ClinicalTrials.gg
CompletedNCT06233474Updated Nov 4, 2026

Study of Intra-articular Allocetra in Knee Osteoarthritis

A Phase 1/2 interventional study of Allocetra and Placebo in Osteoarthritis, Knee, sponsored by Enlivex Therapeutics Ltd.. Completed at 12 sites in 3 countries. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Enlivex Therapeutics Ltd. · Phase 1/2, Interventional, and Treatment

Updated Nov 4, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Osteoarthritis, Knee with a site in Israel — 1 open to participants now, 2 under way, none of them phase 3. Osteoarthritis, Knee · Israel.

Enrollment
2nd of 24
134 · median 60
Started
2024
the only one that year
Phase 1/2
2 of 27
none open now
Registered
26th of 27
by date
Lead sponsor
1 of 27
Enlivex Therapeutics Ltd.

Among the 27 studies in Osteoarthritis, Knee with a site in Israel, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 1/2, and was the 26th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 27 studies in Osteoarthritis, Knee with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Osteoarthritis, Knee with a site in Israel, or all of them as a file.
02

Study summary

This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.

Read the detailed description

Knee osteoarthritis is a degenerative disease driven by physical breakdown of the joint cartilage, together with a chronic inflammation within the knee space. Over time, many patients will develop worsening pain in the joint and functional impairment, which may ultimately require knee replacement.

Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.

This Phase 1/2a study is comprised of an open-label safety run-in stage to characterize safety and tolerability of repeated injections of Allocetra to a target knee , followed by a double-blind randomized stage to evaluate the safety and efficacy of Allocetra repeated injections to the target knee compared to placebo, in moderate to severe knee osteoarthritis patients. Patients in both stages will be followed for up to a year following last treatment. the last treatment.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 45 - 80 years.
  2. Chronic osteoarthritis of index knee with knee-related joint pain
  3. Radiographic evidence of knee osteoarthritis of K-L Grade 2 or 3 in the index knee.
  4. Knee pain assessed daily over a period of 7 days during the screening period and following wash-out of pain medications
  5. Patients with chronic knee pain for at least 3 months who have failed to respond adequately to conventional therapy.
  6. Willing to abstain from other intra-articular treatments and adhere to the protocol restrictions for concomitant medications and therapies during the study.
  7. Women of and all men must agree to use 2 methods of an adequate prior to study entry and for the duration of study participation through 4 weeks following IP administration.

Exclusion criteria

Exclusion Criteria:

  1. Wheelchair bound.
  2. therapy
  3. Any known current or prior tumor of the index knee.
  4. Any known history or current intra-articular or osseous infection of the index knee.
  5. Any evidence of active infection
  6. Any known history of inflammatory arthropathy or crystal-deposition arthropathy
  7. Any known severe systemic cartilage and/or bone disorder, such as, but not limited to, chondrodysplasia, osteogenesis imperfecta.
  8. (BMI) >40.
  9. Any major surgical cartilage treatment within 6 months
  10. Any ligamentous repair or malalignment correction in the index knee within 6 months
  11. Major injury to the index knee, such as torn ligament or severe sprain within 6 months
  12. Clinically relevant knee instability of the index knee
  13. Severe hip osteoarthritis ipsilateral to the index knee.
  14. Clinically significant widespread pain syndromes, e.g., fibromyalgia, long COVID syndrome.
  15. Known coagulopathy, or use of anticoagulation medication or antiaggregant medication;.
  16. certain tumors, severe cardiac, respiratory or hematologic diseases as defined in the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
134 participants (actual)

Study arms

  • Other
    Safety run-in phase - Allocetra increasing dose

    An open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the knee in different doses and select the Allocetra dose and regimen for the randomized phase.

    Drug: Allocetra

  • Placebo comparator
    Randomization phase - Placebo.

    Three intra-articular injections of placebo into the index knee.

    Other: Placebo

  • Experimental
    Randomization phase - Allocetra

    Three intra-articular injections of Allocetra at a selected dose, into the index knee.

    Drug: Allocetra

Interventions

  • DrugAllocetra

    Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state

  • OtherPlacebo

    The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection

    Number and severity of adverse events (AEs), serious adverse events (SAEs) and treatment disruptions/ discontinuations throughout the study from Day 0 and up to 6 months following the last injection

    Time frame: 7 months following Day 0

Secondary outcomes

  1. Weekly average of knee pain.

    Evaluation of change from baseline in weekly average of knee pain as measured using NRS (Numeric Rating Scale ) assessed at 3 months and 6 months from last study treatment. Scores range from 0-10 points, with higher scores indicating greater pain intensity

    Time frame: 4 months and 7 months following Day 0.

  2. Change from baseline in WOMAC total score.

    Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) total score at 3 months, 6 months, and 12 months from last study treatment administration. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

    Time frame: 4 months, 7 months and 13 months following Day 0.

  3. Change in quality of life- Euro Quality of Life-5-dimension (EQ-5D) questionnaire

    Change from baseline in QoL as measured by Euro Quality of Life-5-dimension (EQ-5D) questionnaire at 6 months and at 12 months from last study treatment administration.

    Time frame: 4 months, 7 months and 13 months following Day 0.

07

Study locations

12 sites
  • Sanos Clinic Nordjylland
    Gandrup, 9362, Denmark
  • Sanos Clinic Herlev
    Herlev, 2730, Denmark
  • Sanos Clinic Syddanmark
    Vejle, 7100, Denmark
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Rambam Medical Center
    Haifa, 7651211, Israel
  • Hasharon Medical Center
    Petah Tikva, 4937211, Israel
  • Sheba Medical Center
    Ramat Gan, 5266202, Israel
  • Kaplan Medical Center
    Rehovot, 7661041, Israel
  • Ichilov - Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • IMSP Institutul de Cardiologie
    Chisinau, 2025, Moldova
  • Spitalul Clininc Republican "T. Mosneaga"
    Chisinau, 2025, Moldova
  • IMSP Sptalul Clinic Municipal "Sfanta Treime"
    Chisinau, 2068, Moldova
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Mar 2026, 25 months.

Of 39 phase 1/2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 25 months is close to that.

Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Oct 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Jan 31, 2024
StartActual
Jan 26, 2024
Primary completionActual
Mar 15, 2026
CompletionActual
Oct 15, 2026was May 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Study completion
May 15, 2026→Oct 15, 2026 (actual)
Nov 4, 2026
Enrollment
160 (estimated)→134 (actual)
Nov 4, 2026
Sponsor
Collaborators added: Nordic Bioscience Clinical Development; collaborators removed: Nordic Bioscience Clinical Development (NBCD)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    Study completion May 15, 2026→Oct 15, 2026 (now actual)
    Enrollment 160 (estimated)→134 (actual)
    Sponsor Collaborators added: Nordic Bioscience Clinical Development; collaborators removed: Nordic Bioscience Clinical Development (NBCD)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06233474
Lead sponsor
Enlivex Therapeutics Ltd.
Collaborators
Nordic Bioscience Clinical Development
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Jan 26, 2024
Primary completion
Mar 15, 2026
Completion
Oct 15, 2026
Last update
Nov 4, 2026

Study contacts

Lital Weinfeld-Bergman
study director · Senior Director of Clinical Operations

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion